Phoebe Tsao
Clinical Assistant Professor of Internal Medicine

Available to mentor
Phoebe Tsao
Clinical Assistant Professor
  • Qualifications
  • Center Memberships
  • Recent Publications
    • Qualifications
    • Hematology/Oncology Fellowship
      University of Michigan–Ann Arbor, Ann Arbor, 2021
    • Chief Medical Residency
      University of Michigan–Ann Arbor, Ann Arbor, 2018
    • Internal Medicine Residency
      University of Michigan–Ann Arbor, Ann Arbor, 2017
    • MSc
      University of Michigan Medical School, Ann Arbor, 2022
    • MD
      University of Michigan Medical School, Ann Arbor, 2014
    • BA
      University of Pennsylvania, Philadelphia, 2009
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Eisenberg Family Depression Center
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70.
      Chung DH, Caverly TC, Schipper MJ, Saini SD, Gulati R, Rose BS, Caram MV, Tsao PA, Stensland KD, Bryant A. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 5028 - 5028. DOI:10.1200/jco.2024.42.16_suppl.5028
    • Journal Article
      Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer
      Caram MEV, Kumbier K, Tsao PA, Burns J, Sparks JB, Stensland KD, Reichert ZR, Alumkal JJ, Hollenbeck BK, Shahinian V, Tsodikov A, Skolarus TA. Cancer Medicine, 2024 Jun 1; 13 (12): DOI:10.1002/cam4.7334
    • Journal Article
      Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.
      Nguyen CB, Kobe C, Kumbier KE, Bauman J, Burns JA, Tsao PA, Sparks JB, Skolarus TA, Caram MEV. JCO Oncol Pract, 2024 Jan; 20 (1): 59 - 68. DOI:10.1200/OP.23.00258
      PMID: 38085028
    • Journal Article
      A Positive Distress Screen…Now What? An Updated Call for Integrated Psychosocial Care.
      Tsao PA, Fann JR, Nevedal AL, Bloor LE, Krein SL, Caram MEV. J Clin Oncol, 2023 Nov 1; 41 (31): 4837 - 4841. DOI:10.1200/JCO.22.02719
      PMID: 37441747
    • Journal Article
      Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.
      Tsao PA, Burns J, Kumbier K, Sparks JB, Entenman S, Bloor LE, Bohnert ASB, Skolarus TA, Caram MEV. Cancer Med, 2023 Aug; 12 (15): 16490 - 16501. DOI:10.1002/cam4.6237
      PMID: 37325888
    • Proceeding / Abstract / Poster
      Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer.
      Kobe C, Nguyen CB, Kumbier KE, Bauman J, Burns JA, Tsao PA, Sparks JB, Caram MV. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): e18878 - e18878. DOI:10.1200/jco.2023.41.16_suppl.e18878
    • Journal Article
      Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
      Caram MEV, Kumbier K, Burns J, Sparks JB, Tsao PA, Stensland KD, Washington SL, Hollenbeck BK, Shahinian V, Skolarus TA. Cancer Med, 2023 Mar; 12 (6): 6945 - 6955. DOI:10.1002/cam4.5490
      PMID: 36790037
    • Proceeding / Abstract / Poster
      Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer
      Kobe C, Nguyen CB, Kumbier KE, Bauman J, Burns JA, Tsao PA, Sparks JB, Caram MV. JOURNAL OF CLINICAL ONCOLOGY, 2023 41 (16):